Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
EVO 
Evotec SE ADR (EVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/22/2025: EVO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.45
1 Year Target Price $5.45
| 1 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.68% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.42B USD | Price to earnings Ratio - | 1Y Target Price 5.45 |
Price to earnings Ratio - | 1Y Target Price 5.45 | ||
Volume (30-day avg) 6 | Beta 1.08 | 52 Weeks Range 2.84 - 5.64 | Updated Date 10/22/2025 |
52 Weeks Range 2.84 - 5.64 | Updated Date 10/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.01% | Operating Margin (TTM) -16.7% |
Management Effectiveness
Return on Assets (TTM) -2.4% | Return on Equity (TTM) -16.75% |
Valuation
Trailing PE - | Forward PE 59.88 | Enterprise Value 1085009593 | Price to Sales(TTM) 1.83 |
Enterprise Value 1085009593 | Price to Sales(TTM) 1.83 | ||
Enterprise Value to Revenue 1.19 | Enterprise Value to EBITDA -21.37 | Shares Outstanding 355198252 | Shares Floating 130516727 |
Shares Outstanding 355198252 | Shares Floating 130516727 | ||
Percent Insiders - | Percent Institutions 2.72 |
Upturn AI SWOT
Evotec SE ADR
Company Overview
History and Background
Evotec SE was founded in 1993 in Hamburg, Germany. Initially focused on high-throughput screening, it evolved into a leading drug discovery alliance and development company. Key milestones include strategic acquisitions and partnerships that expanded its service offerings and global reach.
Core Business Areas
- EVT Execute: Provides integrated drug discovery solutions from target identification to preclinical development, including screening, medicinal chemistry, and ADME/PK services.
- EVT Innovate: Focuses on proprietary research programs aimed at discovering and developing novel therapeutics in areas such as neurodegenerative diseases, oncology, and metabolic diseases.
- Just - Evotec Biologics: Offers process development and manufacturing services for biologics, including cell line development, upstream and downstream processing, and formulation.
Leadership and Structure
Dr. Werner Lanthaler is the Chief Executive Officer. The company has a management board and supervisory board, with a global organizational structure across multiple sites in Europe and North America.
Top Products and Market Share
Key Offerings
- Drug Discovery Services: Comprehensive drug discovery solutions, including target validation, assay development, high-throughput screening, medicinal chemistry, and preclinical development. Evotec doesn't directly sell a drug, but develops services in partnership with pharmaceutical companies. Market share data for the overall CRO market is fragmented, with competition from companies like Charles River Laboratories, WuXi AppTec and Labcorp Drug Development.
- Biologics Development and Manufacturing: Process development, cell line development, and GMP manufacturing of biologics. Similar to Drug Discovery Services, the market share and revenue for this are within the CRO/CDMO space. Main competitors are Thermo Fisher Scientific and Catalent.
Market Dynamics
Industry Overview
The drug discovery and development services market is experiencing significant growth, driven by increasing R&D spending by pharmaceutical companies, the complexity of drug development, and the need for specialized expertise.
Positioning
Evotec is positioned as a leading provider of integrated drug discovery solutions, offering a wide range of services and expertise. Its competitive advantages include its scientific expertise, technology platforms, and global presence.
Total Addressable Market (TAM)
The global drug discovery market is projected to reach several hundred billion USD. Evotec is positioned to capture a significant portion of this market through its comprehensive service offerings and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Comprehensive service portfolio
- Scientific expertise and technology platforms
- Strong partnerships with pharmaceutical companies
- Global presence
- Innovative research programs
Weaknesses
- Reliance on R&D spending by pharmaceutical companies
- Competition from larger CROs
- High operational costs
- Exposure to currency fluctuations
Opportunities
- Expanding into new therapeutic areas
- Increasing demand for biologics development and manufacturing
- Growth in emerging markets
- Strategic acquisitions and partnerships
- Leveraging AI and machine learning in drug discovery
Threats
- Economic downturns
- Increased competition
- Regulatory changes
- Technological disruptions
- Intellectual property risks
Competitors and Market Share
Key Competitors
- CRL
- WX
- LH
Competitive Landscape
Evotec's advantages lie in its integrated service offerings and scientific expertise. Disadvantages include its smaller size compared to some larger CROs and reliance on external funding and pharmaceutical R&D spending.
Major Acquisitions
Just Biotherapeutics
- Year: 2019
- Acquisition Price (USD millions): 90
- Strategic Rationale: Expanded Evotec's capabilities in biologics development and manufacturing, adding significant value to its integrated service offerings.
Growth Trajectory and Initiatives
Historical Growth: Evotec has demonstrated strong revenue growth driven by its expanding service offerings and strategic acquisitions. The rate of growth has varied depending on market conditions and specific contracts.
Future Projections: Analyst estimates can be found on financial news sites, and they typically project continued growth for Evotec, driven by the growing demand for drug discovery and development services. Projections consider the company's backlog, partnerships, and market trends.
Recent Initiatives: Recent initiatives include expanding its biologics manufacturing capacity, investing in AI-driven drug discovery platforms, and forming new strategic partnerships with pharmaceutical companies.
Summary
Evotec is a leading drug discovery and development company with a strong portfolio of services and strategic partnerships. It operates in a growing market but faces competition from larger CROs. Recent initiatives and acquisitions position it for future growth, although economic uncertainties and regulatory changes pose potential challenges. The company needs to carefully manage its costs and maintain its scientific expertise to remain competitive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Verify all information with official sources before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evotec SE ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2009-12-04 | CEO & Management Board Member Dr. Christian Wojczewski Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 4759 | Website https://www.evotec.com |
Full time employees 4759 | Website https://www.evotec.com | ||
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.